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Abstract
Nasopharyngeal carcinoma (NPC) is a unique EBV-associated epithelial malignancy, showing highly invasive and metastatic
phenotype. Despite increasing evidence demonstrating the critical role of cancer stem-like cells (CSCs) in the maintenance
and progression of tumors in a variety of malignancies, the existence and properties of CSC in EBV-associated NPC are
largely unknown. Our study aims to elucidate the presence and role of CSCs in the pathogenesis of this malignant disease.
Sphere-forming cells were isolated from an EBV-positive NPC cell line C666-1 and its tumor-initiating properties were
confirmed by in vitro and in vivo assays. In these spheroids, up-regulation of multiple stem cell markers were found. By flow
cytometry, we demonstrated that both CD44 and SOX2 were overexpressed in a majority of sphere-forming C666-1 cells.
The CD44+SOX2+ cells was detected in a minor population in EBV-positive xenografts and primary tumors and considered
as potential CSC in NPC. Notably, the isolated CD44+ NPC cells were resistant to chemotherapeutic agents and with higher
spheroid formation efficiency, showing CSC properties. On the other hand, microarray analysis has revealed a number of
differentially expressed genes involved in transcription regulation (e.g. FOXN4, GLI1), immune response (CCR7, IL8) and
transmembrane transport (e.g. ABCC3, ABCC11) in the spheroids. Among these genes, increased expression of CCR7 in
CD44+ CSCs was confirmed in NPC xenografts and primary tumors. Importantly, blocking of CCR7 abolished the sphere-
forming ability of C666-1 in vitro. Expression of CCR7 was associated with recurrent disease and distant metastasis. The
current study defined the specific properties of a CSC subpopulation in EBV-associated NPC. Our findings provided new
insights into developing effective therapies targeting on CSCs, thereby potentiating treatment efficacy for NPC patients.
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Introduction
Non-keratinizing nasopharyngeal carcinoma (NPC) is a distinct
epithelial malignancy arising from the head and neck region. It
consistently associates with Epstein-Barr virus (EBV) and shows
unique clinical and pathological feature. With the clonal
expansion of a single EBV-infected progenitor cell, constitutive
expression of viral latent genes and accumulation of multiple
genetic changes contribute to the initiation and progression of this
cancer [1,2].
NPC demonstrates strong geographic preference, showing high
prevalence in Southeast Asia, especially in the Cantonese region
including Hong Kong with an annual incidence of 25–50 per
100,000 persons [1]. The mainstay treatment for NPC is either
radiotherapy or combined chemo-radiotherapy which shows over
90% cure rate in patients with early disease stage [3]. However,
the outcome for patients with advanced loco-regional diseases and
distant metastases are unsatisfactory. Significant rates of distant
relapse and metastasis still occur in these patients after radiother-
apy or chemo-radiotherapy. One of the major mechanisms for
such post-therapeutic recurrence of NPC has been suggested by
the ‘cancer stem-like cell’ (CSC) proposition [4].
According to the CSC model, cancers are hierarchically
organized similar to normal tissues and cancer growth and
progression are driven by a small subset of tumor cells with stem
cell-like properties, the CSCs. This rare cell subpopulation is
responsible for tumor initiation, maintenance and regeneration
[4,5]. CSCs have been identified in various human malignancies
such as breast, prostate, ovarian, lung and head and neck
carcinoma [5,6,7,8,9]. The abilities of these cells to initiate tumor
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growth, sustain self-renewal and facilitate drug resistance have
been extensively proven. Considering the unique properties of
CSCs, the relapse of tumors are suggested to be due to the failure
to eradicate all CSCs and surviving CSCs then reconstitute the
tumor in local and distant regions.
Although CSCs have been shown to be vital in the
development of most cancers, information regarding their
existence in EBV-associated NPC is scarce. Either research
was conducted using EBV-negative cell lines or was unable to
elucidate any functional CSCs [10,11,12]. Our group has
previously established several EBV-positive tumor lines from
NPC patients in endemic regions [13,14,15,16] and using these
native EBV-positive tumor cells, we aimed to identify and
characterize functional NPC CSCs.
In this study, sphere-forming cells (‘spheroids’) from EBV-
positive cell line C666-1 were isolated and their stem cell-like
properties were confirmed. We revealed that CD44 and SOX2
were expressed in a majority of these CSCs. By microarray
analysis, aberrantly expressed cellular genes in CSCs were
identified. Interestingly, CCR7, a cell surface chemokine
receptor, was found to be consistently expressed in NPC lines
and primary tumors. Coincidentally, it was overexpressed in our
identified NPC CSCs and the neutralization of this receptor
abolished the sphere-forming ability of C666-1. Our current
study provided first evidence for the presence of tumorigenic
CSCs in EBV-positive NPC and CCR7 might play a role in
their tumorigenic function. The above findings will enhance our
understanding on the nature of NPC CSCs, which is crucial in
developing more effective therapeutic intervention against this
disease.
Results
CSC Capabilities of EBV-positive NPC-derived Spheroids
CSCs possessed the capacity to form anchorage-independent
tumor spheres when grown in specialized serum-free medium. As
shown in Figure 1A, free-floating tumor spheres were formed
when the dissociated C666-1 cells were cultured on uncoated
plates in serum-free stem cell medium. Non-adherent spheroids
were observable at 6–8 days and they were enzymatically
dissociated into single cells for passage weekly. Distinct pro-
totypical spheroids were formed 28 days after plating. This self-
renewing floating tumor spheres could be passaged serially and
grown for more than 3 months. When single cells from spheroids
was cultured in adherent plates with complete medium (RPMI-
1640 with 10% FBS), floating cells adhered to the plate and
formed systematic colonies, showing epithelial cell morphology
similar to that of parental monolayer C666-1 cells (Fig. 1A, right
panel).
To measure the tumorigenic capacity of spheroids, various
numbers of sphere-forming cells and unselected parental C666-1
cells were injected subcutaneously into flanks of nude mice. We
found that 10,000 sphere-forming cells could form tumors in all
inoculated mice (Table 1). Injection of 1,000 spheroid cells
occasionally formed one tumor out of six mice. However, at least
500,000 unselected C666-1 cells were necessary for tumor
formation. The spheroid cells showed at least 50 times higher
tumorigenic potential than the unselected cells. To further verify
whether the sphere-forming cells are capable of serially propagat-
ing in nude mice, xenografts developed from spheroids were
serially engrafted into nude mice. All of them showed successful
serial transplantations and tumors were observable at 3–4 weeks
(data not shown).
We then examined the expression pattern of multiple stem cell
markers and surface antigens in these spheroids. By qRT-PCR
analysis, we found that the expression of multiple stem cell markers
(OCT4, NANOG, ALDH1, CD44 and CD133) in spheroids was
significantly higher than that of the monolayer parental C666-1
cells (all P,0.05, Fig. 1B). Increased expression of CKIT, KLF4
and KLF5 in the spheroids was also noted. Although we did not
detect up-regulation of SOX2 transcription in the sphere-forming
cells, SOX2-expressing (SOX2+) cells were shown to be highly
enriched in the spheroids (70.862.16%) by flow cytometry (all
P,0.001, Fig. 1C). We also detected SOX2 expression in
0.7760.13% of cells in NPC xenografts. The findings confirmed
that the spheroids derived from EBV-positive C666-1 cells exhibit
CSC phenotypes.
Sphere-forming CSCs Express Cell Surface Protein CD44
Since the transcription of CD44 and CD133 were signifi-
cantly increased in spheroids, we then verified whether the
expression of these CSCs surface markers was specific to NPC
sphere-forming cells. By flow cytometry and immunofluores-
cence staining, we have demonstrated that a majority of the
cells in C666-1 spheroids (84.1461.12%) were CD44 positive
(Fig. 1D and Fig. S1). CD44+ cells were also found as
a subpopulation of the parental C666-1 cells (5.2861.29%) and
three NPC xenografts, xeno-666 (12.3161.97%), xeno-2117
(9.5861.80%), and C17 (17.3161.76%) (Fig. 1D). However,
CD133-expressing cells were detected in only 32.1162.35% of
spheroids cells and 1.9060.84% of parental C666-1 cells.
Furthermore, CD133+ cells were completely absent in 2 of the
xenografts (xeno-666 and xeno-2117) (Fig. S2). Thus, we
proposed that CD44 is a common candidate CSC surface
marker for EBV-positive NPC.
CD44+ Cells Express SOX2 and Exhibit Higher Clone- and
Sphere-forming Efficiency
Expression of stem cell transcription factor SOX2 was
consistently detected in a tumor cell sub-population in primary
NPC and is believed to be a potential marker for NPC CSCs [12].
Consequently, we assessed the co-expression of CD44 and SOX2
in spheroids and unselected monolayer C666-1 cells, as well as 3
xenografts and 5 primary tumors by flow cytometry. As shown in
Figure 2, over 60% of spheroid cells (66.5762.72%) expressed
both CD44 and SOX2. Coincidentally, SOX2 expression was
rarely detected in CD442 fraction of C666-1 sphere-forming cells,
suggesting a preferential expression of this stem cell transcription
factor in CD44+ cells. Co-expression of CD44 and SOX2 was also
detected in 0.1–9% of cells in the NPC cell line, xenografts and
primary tumors. The findings implied that CD44+SOX2+ cells
are potential CSCs in NPC. To prove this hypothesis, we
performed functional assays in CD44+ and CD442 cells isolated
from parental C666-1 cells. Representative figures of CD44
expression in the isolated CD44+ and CD442 cells are shown in
Figure S3. As shown in Figure 3A, significantly higher clone
formation efficiency was detected in the CD44+ cell fraction than
that of CD442 fraction (P,0.01). Moreover, CD44+ cells could
generate significantly higher number of spheroids compared with
the CD442 cells (P,0.001, Fig. 3B).
Proliferation of CD44+ Cells
By WST1 proliferation assay, CD44+ cells exhibited a signifi-
cantly higher proliferation rate when compared to the CD442
and parental C666-1 cells, while CD442 cells showed a signifi-
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cantly lower proliferation rate when compared to parental C666-1
cells (all P,0.01, Fig. 3C).
Hierarchical Relationship of CD44+ and CD442 Cells
Consistent with CSC properties, we revealed that the sorted
CD44+ C666-1 cells possessed the ability to give rise to both
CD44+ and CD442 cells. As shown in Fig. 3D, a decrease in
CD44+ cell fraction in the sorted CD44+ cells was detected by
flow cytometry over time. It is likely that sorted CD44+ cells give
rise to a heterogeneous population through downregulation of
CD44 in a subset of these cells after culture in vitro. However, no
significant change in the percentage of CD44+ cell fraction in both
unsorted parental and sorted CD442 cells was detected after 3–6
days of passage. The results suggest a hierarchical relationship of
CD44+ and CD442 cells in EBV-associated NPC.
Chemoresistance of CD44+ Cells
To examine the chemoresistance of CD44+ cells to anti-cancer
chemotherapeutic agents, we performed cell survival assays for the
CD44+ and CD442 cell fractions treated with fluorouracil (5-FU),
cisplatin or doxorubicin. The CD44+ cell fraction of C666-1
exhibited stronger chemoresistance to 5-FU compared with the
parental unselected C666-1 cells and CD442 fraction (all P,0.05)
(Fig. 3E). The chemoresistance of CD44+ cells towards cisplatin or
doxorubicin was similar to CD442 and parental C666-1 cells
(data not shown).
Differentially Expressed Genes in NPC-derived Spheroids
To comprehensively characterize the properties of NPC CSCs,
we examined the expression of cellular and EBV genes in NPC
sphere-forming cells using olignonucleotide microarray and qPCR
assays. Firstly, we assessed EBV copy number and the expression
level of EBV genes including EBNA1, LMP1, LMP2A, BARF1,
EBER1 and BZLF1 in C666-1 spheroids. The sphere-forming
cells showed higher EBV copy number and latent gene expression
than the parental C666-1 cells (Fig. 4A). We detected significant
elevation of EBER1, BARF1 and LMP1 expression in the
spheroids (all P,0.05). No significant difference in the expression
of EBV immediate-early lytic gene BZLF1 was observed between
the spheroids and parental C666-1 cells.
The cellular genes differentially expressed in spheroids and
monolayer C666-1 cells were identified by microarray analysis.
Expression of 830 and 260 genes were found to show more than 5-
fold increase and decrease in the sphere-forming cells respectively.
Gene ontology analysis revealed that the 5 major molecular
function catalogs enriched in the differentially expressed genes
include: regulation of transcription, immune response, regulation
of apoptosis, cell adhesion, and transmembrane transport, each
with significant P values (Table 2 and Table S2). A selection of
differentially expressed genes was listed in Table 2. By qRT-PCR,
we validated the expression of selected genes involved in
maintaining stem cell properties in the spheroids and parental
C666-1 (Fig. 4B). Significantly increased expression (P,0.05) of
chemokines and receptors (IL8, CCL4, CX3CL1, CCR7),
signaling pathway-related genes (FOXN4 and GLI1), and cell
adhesion molecules (SELE) were confirmed in the spheroids
(Fig. 4B). Notably, two ATP-binding cassette (ABC) transporter
genes (ABCC3 and ABCC11) are also highly expressed in the
spheroids (all P,0.01). The overexpression of these genes could be
responsible for the chemoresistant feature of NPC CSCs (Fig. 4B).
Expression of CCR7 in CD44+ CSCs of NPC
Among the differentially expressed genes, CCR7, a chemokine
receptor, showed the highest fold change in expression in the
spheroids by microarray analysis and was thus selected for further
investigation. By flow cytometry, a significant enrichment of
CCR7+ cells was detected in spheroids when compared to
parental cells (all P,0.001, Fig. 4C). We also detected CCR7
expression in 0.5360.14% and 2.8761.53% of cells in xenografts
and primary tumors respectively. Multicolor flow cytometric
analysis revealed that a majority of CCR7+ cells were co-
expressed with CD44. CD44+CCR7+ cells were enriched in
spheroids when compared to the xenografts and primary tumors
(all P,0.001, Fig. 4D). This candidate CSC fraction was also
detected in NPC tumor lines and primary tumors.
Since CCR7 was highly expressed in NPC sphere-forming cells
and correlated with lymph node metastasis in various human
cancers, we then determined the association of CCR7 expression
with the clinical parameters in 39 primary NPC cases. Represen-
tative CCR7 expression patterns in primary tumors were shown in
Figure 5. CCR7 expression is significantly correlated with CD44
expression in these cases (Fig. S4). Among the NPC samples, 8
(20.5%) were negative for CCR7 staining. Weak, medium and
high expression of CCR7 were detected in 13, 7 and 11 primary
cases respectively. Importantly, we found that CCR7 expression
correlated with the presence of recurrent disease and distant
metastasis (Table 3). The finding implied that the CCR7-
expressing cells might contribute to disease progression.
To investigate the role of CCR7 in NPC CSC, we utilized
a CCR7-blocking antibody to neutralize its function in the
parental, CD44+ and CD442 C666-1 cells. The cells were
treated with 0–250 ng/mL CCR7 blocking antibody for 24 hrs
and the proliferation of cells were measured by WST1 assay.
Observable decrease in cell proliferation was observed in the
CD44+ cell fraction when compared to CD442 and parental
C666-1 cells. (Fig. 6A). Reduced clone formation efficiency was
also found in C666-1 cells treated with CCR7 blocking
antibody (P,0.05, Fig. 6B). Importantly, sphere-forming capa-
bility was significantly inhibited after CCR7 blocking antibody
treatment (P,0.001, Fig. 6C). The results provided evidences
for the involvement of CCR7 in maintaining CSC function in
NPC.
Discussion
This study provides the first evidence on the existence of highly
tumorigenic CSCs in EBV-positive NPC. We have developed
a protocol to obtain EBV-positive NPC CSCs for further
characterization. Formation of spheroids is a major functional
Figure 1. Sphere-forming cells with stem cell-like properties in EBV-positive NPC. (A) Free-floating tumor spheres were formed from EBV-
positive C666-1 cells (left panel) and they demonstrated ability to differentiate comparably to monolayer cells upon administering complete medium
(right panel). (B) By qRT-PCR, multiple stem cell-related genes (OCT4, NANOG, ALDH1, CKIT, CD44, CD133) were enriched in spheroids when
compared to parental C666-1. Transcription of SOX2 was not increased in the spheroids. (C) SOX2 protein was frequently expressed in C666-1 sphere-
forming cells. By flow cytometry, SOX2-positive (SOX2+) cells were found to be enriched in and constituted over 60% of sphere-forming cell
population. (D) Over 80% of sphere-forming cells expressed cell surface marker CD44 while CD44+ cells in detected in parental C666-1 and other NPC
xenografts were significantly lower (all P,0.001). Histograms denoting mean 6 SE (n$3) with statistical significance calculated by t-test (*P,0.05,
**P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0052426.g001
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characteristic of CSCs in human cancers [17]. In this study, we
successfully isolated a potential CSC population in the EBV-
positive NPC cell line C666-1 through harvesting tumor spheres.
The stem cell-like properties in sphere-forming C666-1 sub-
population obtained were confirmed by demonstrating the up-
regulation of multiple stem cell-associated genes and high
tumorigenicity in nude mice [9,18,19]. Through comprehensive
characterization of the NPC spheroids, tumor lines and primary
tumor, we have revealed that CD44 and SOX2 are potential CSC
markers for NPC. Cell surface markers are crucial in identifying
CSCs from among the heterogenic tumor cells. CD44 is
a hyaluronan receptor and has been demonstrated to be marker
for CSCs in head and neck squamous cell carcinoma (HNSCC)
[7]. In this study, we showed that CD44 expression was enriched
in NPC CSCs. As evidenced from the significantly higher sphere-
forming capability of CD44+ NPC cells, CSC subpopulation was
confirmed to be enriched in this CD44+ fraction. The resistance of
CD44+ cells to 5-FU treatment is in concordance to proposed
CSC properties. In addition to CD44, our study also detected the
enrichment of SOX2-expressing cells in the spheroids, the
functional NPC CSCs. Interestingly, similar level of SOX2
transcripts was found in both sphere-forming and parental
C666-1 cells. According to our unpublished finding, the increased
SOX2 protein expression may be due to the loss of the SOX2-
repressing miRNAs (miR-183 and miR-203) in the spheroids.
SOX2 is a transcription factor that controls pluripotency in
embryonic and adult-tissue specific stem cells [20]. It regulates
stem cell self-renewal and differentiation and is frequently found to
be up-regulated in human cancers [21]. Zhang et al. (2010) has
suggested that SOX2+ cells possess stemness properties [12]. They
have demonstrated that SOX2 was expressed and co-localized
with OCT4 in primary NPC. In concordance with Zhang’s
findings, our results revealed that CD44+ SOX2+ cells are
enriched in NPC CSCs.
Isolation of sphere-forming cells in the EBV-positive NPC cell
line provided us an opportunity to assess the expression of EBV
latent and lytic genes in CSC. Notably, elevated expression of
EBV latent gene products, EBER1, BARF1 and LMP1 were
detected in the CSC subpopulation. We have previously
demonstrated that the expression of EBER confers resistance
to apoptotic stress [22]. The high EBER expression in NPC
CSCs suggests that this cell subpopulation maybe more resistant
to apoptosis. On the other hand, LMP1 can induce EMT via
Twist or Snail, which coincides with the acquisition of CSC
properties [23,24,25]. In addition, Kondo et al. have also
recently shown that LMP1 induces CD44+ CSC in nasopha-
ryngeal epithelial cells [26]. The findings imply that LMP1
expression may play a critical role in CSC maintenance in this
EBV-associated malignancy.
In addition to the EBV latent genes, our microarray analysis
revealed an overexpression of CCR7 in the NPC-derived
spheroids. The enrichment of CCR7+ cell population in the
sphere-forming cells was confirmed by flow cytometry. CCR7 is
a chemokine receptor that mediates cell migration in response to
its ligand CCL21 [27]. It is likely that high CCR7 receptor
expression in sphere-forming cells will enhance its sensitivity to the
ligands and activate its downstream signaling. Aberrant CCR7
expression in human malignancies has been linked to cell survival
and metastatic pathways. The CCL21/CCR7 pathway may play
a crucial role in the metastasis of CCR7+ CSCs to lymph nodes
[28]. Overexpression of CCR7 in CSCs is likely to contribute to
the frequent cervical lymph node metastases in NPC patients [29].
The abolished sphere-forming ability of the NPC cells after CCR7T
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neutralization suggested CCR7 might also regulate CSC proper-
ties in NPC.
Drug resistance is an important characteristic of CSCs, which
forms the basis to tumor recurrence after chemotherapeutic
treatments [30]. Increased expression of ATP-binding cassette
(ABC) transporter family is responsible for the efflux of therapeutic
drugs and is a common mechanism for maintaining drug
resistance in CSCs [31,32]. As shown in our microarray study,
significant overexpression of ABCC3 and ABCC11 was found in
the sphere-forming cells. ABCC3 is a member of the multidrug
resistance protein (MRP) subfamily and was shown to be over-
expressed in ovarian carcinoma and doxorubicin-resistant lung
cancer cell line [33,34]. ABCC3 overexpression may contribute to
the drug resistant properties in the cisplatin-/doxorubicin-resistant
C666-1 cell lines (Fig. S5). ABCC11 is another MRP family
member up-regulated in NPC-derived spheroids. It is the main
transporter for 5-fluorouracil (5-FU) [35] which is one of the main
chemotherapeutic drugs for NPC [3]. Over-expression of
ABCC11 in sphere-forming cells suggests that the CSC population
in NPC is resistant to chemotherapeutic drugs and thus contribute
to tumor recurrence.
Hedgehog signaling pathway is an important regulator of CSC
maintenance and function. In C666-1 spheroids, the microarray
study has also detected the increased expression of GLI1, a major
transcription activator of hedgehog signaling pathway. In ovarian
carcinoma, GLI1 was reported to regulate the growth of CSCs
[36]. To elucidate the role of GLI1 and hedgehog pathway in
NPC CSCs, the effects of silencing GLI1 expression on the
formation and tumorigenic properties of sphere-forming cells will
be examined. The elucidation on signaling mechanisms regulating
the proliferation and apoptosis of NPC CSCs will benefit therapies
targeted on this subpopulation of drug resistant cells.
In conclusion, we have identified highly tumorigenic CSCs in
EBV-positive NPC and this subpopulation could be enriched by
cell surface CD44 and identified together with SOX2. Our study
has discovered several crucial molecules including CCR7 and
ABCC11 involved in the maintenance of NPC CSC functions.
The present findings provided a foundation on the development of
Figure 2. CD44 and SOX2 as CSC markers. By flow cytometry, SOX2 was found to be preferentially expressed on CD44+ cells and coincidentally,
SOX2 expression was rarely detected in CD442 cells. Cells coexpressing both CD44 and SOX2 were found to be enriched in spheroids. Histograms
denoting mean 6 SE (n$3) with statistical significance calculated by t-test (*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0052426.g002
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Figure 3. CD44+ cells with stem cell-like properties in EBV-positive NPC. CD44+ cell fraction exhibited a significantly higher (A) clone
formation efficiency and (B) sphere-forming efficiency when compared to CD442 cell fraction. In addition, (C) CD44+ cells exhibited significantly
higher proliferation rate than CD442 cells. (D) Developmental hierarchy feature of CD44+ cells. Percentage of CD44+ cells were continually reduced
in the isolated CD44+ cell fraction over time. (E) CD44+ cells exhibited higher resistance to 5-FU treatment when compared to the CD442 and
parental C666-1 cells. All graphs denoting mean 6 SE (n$3) with statistical significance calculated by t-test (*P,0.05, **P,0.01, ***P,0.001).
doi:10.1371/journal.pone.0052426.g003
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Figure 4. Overexpression of multiple EBV and cellular genes in sphere-forming NPC cells. (A) By qRT-PCR, multiple EBV genes (EBER,
BARF1, LMP1, LMP2A, EBNA1 and BZLF1) were found to be overexpressed in spheroids when compared to monolayer C666-1 cells. EBV copy number
in these cells was determined by qPCR. (B) Selected genes aberrantly expressed in spheroids were confirmed by qRT-PCR. The significantly
upregulated genes include chemokines and receptors (CCR7, CCL4, CX3CL1 and IL-8), cell adhesion molecule SELE, signaling molecules (GLI1, FOXN4)
and ABC transporters (ABCC3, ABCC11). (C) Cell surface-expressed CCR7 was found to be frequently expressed in sphere-forming cells (.60%) by flow
cytometry. The CCR7+ cell subpopulation was also detected in NPC lines and primary tumors (,5%). (D) CD44+CCR7+cells were also found to be
enriched in spheroids. Histograms denoting mean 6 SE (n$3) with statistical significance calculated by t-test (*P,0.05, **P,0.01, *** P,0.001).
doi:10.1371/journal.pone.0052426.g004
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Table 2. Selection of aberrantly expressed genes in sphere-forming cells compared to monolayer C666-1 cells.
Genes Gene Description Genbank Accession no. Fold Changes
Regulation Transcription (P value: 0.0041; n=132)
FOXN4 Forkhead box N4 NM_213596 43.28
EGR1 Early growth response 1 NM_001964 33.48
HOXA7 Homeobox A7 NM_006896 20.43
STAT4 Signal transducer and activator of transcription 4 NM_003151 11.99
NFATC1 Nuclear factor of activated T-cells, cytoplasmic, calcineurin-dependent 1 (NFATC1),
transcript variant 3
NM_172387 8.97
GLI1 Glioma-associated oncogene homolog 1 (zinc finger protein) NM_005269 8.84
PAX6 Paired box gene 6 (aniridia, keratitis), transcript variant 2 NM_001604 7.70
RUNX1 Runt-related transcription factor 1 (acute myeloid leukemia 1; aml1 oncogene),
transcript variant 2
NM_001001890 5.25
MBD2 Methyl-CpG binding domain protein 2, transcript variant testis-specific NM_015832 222.31
Immune response (P value: 0.0051; n=54)
CCR7 Chemokine (C-C motif) receptor 7 (CCR7) NM_001838 169.42
IL1B Interleukin 1, beta NM_000576 43.24
CCL4 Chemokine (C-C motif) ligand 4 (CCL4) NM_002984 20.85
RAG1 Recombination activating gene 1 NM_000448 16.95
IL7R Interleukin 7 receptor NM_002185 13.75
CX3CL1 Chemokine (C-X3-C motif) ligand 1 (CX3CL1) NM_002996 9.49
IL8 Interleukin 8 NM_000584 8.00
CD86 CD86 molecule, transcript variant 2 NM_006889 7.78
TLR7 Toll-like receptor 7 NM_016562 5.28
HLA-G HLA-G histocompatibility antigen, class I, G NM_002127 26.94
Cell adhesion (P value: 0.032; n=50)
SELE Selectin E NM_000450 149.51
TNC Tenascin C NM_002160 14.62
VCAN Versican NM_004385 8.42
ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha), transcript variant 1 NM_003474 7.41
SLAMF7 SLAM family member 7 NM_021181 6.47
ICAM5 intercellular adhesion molecule 5, telencephalin NM_003259 210.99
RHOB ras homolog gene family, member B NM_004040 210.80
Transmembrane Transport (P value: 0.0041; n =37)
SLC22A15 Solute carrier family 22 (organic cation transporter), member 15 NM_018420 27.91
SLC24A3 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 NM_020689 24.87
SLC22A4 Solute carrier family 22 (organic cation transporter), member 4 NM_003059 14.45
ABCC11 ATP-binding cassette, sub-family C (CFTR/MRP), member 11, transcript variant 2 NM_033151 11.99
SLC16A6 Solute carrier family 16, member 6 (monocarboxylic acid transporter 7) NM_004694 8.98
PDPN Podoplanin (PDPN), transcript variant 1, NM_006474 7.58
ABCC3 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 5.34
Positive regulation of apoptosis (P value: 0.026; n=34)
MAL Mal, T-cell differentiation protein (MAL), transcript variant a NM_002371 17.84
BCL11B B-cell CLL/lymphoma 11B (zinc finger protein), transcript variant 1 NM_138576 10.52
CASP1 Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase),
transcript variant alpha
NM_033292 9.30
HDAC6 Histone deacetylase 6 BC011498 5.70
CUL3 Cullin 3 NM_003590 5.29
CASP8 Caspase 8, apoptosis-related cysteine peptidase, transcript variant E NM_033358 5.08
TNFRSF10B Tumor necrosis factor receptor superfamily, member 10b NM_003842 25.81
TIA1 TIA1 cytotoxic granule-associated RNA binding protein, transcript variant 1 NM_022037 26.59
doi:10.1371/journal.pone.0052426.t002
Cancer Stem-Like Cells in EBV-Positive NPC
PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e52426
Figure 5. Immunohistochemical analysis of CCR7 and CD44 expression in primary NPC. Representative primary NPC cases with high (A),
medium (B), low (C) expression of CCR7. (D) Primary NPC with absence of CCR7 expression was shown. CCR7 staining were detected in few infiltrating
lymphocytes, but not in the tumor cells. Primary tumors with high (E) and medium (F) CD44 expression were shown. In (G) and (H), weak CD44
expression was detected in the tumor cells while strong CD44 staining in infiltrating lymphocytes was commonly found.
doi:10.1371/journal.pone.0052426.g005
Cancer Stem-Like Cells in EBV-Positive NPC
PLOS ONE | www.plosone.org 10 December 2012 | Volume 7 | Issue 12 | e52426
novel therapies targeting NPC CSC that may potentiate efficacy of
current treatments.
Materials and Methods
Cell Lines, Xenografts and Primary Tumors
An EBV-positive NPC cell line (C666-1) and 3 xenografts (xeno-
666, xeno-2117 and C17) were included in this study [13,14,15].
Parental C666-1 was cultured in RPMI-1640 (Sigma-Aldrich)
supplemented with 10% fetal bovine serum (FBS) (Invitrogen). For
tumor sphere culture, cells were cultured in serum-free DMEM-
F12 (Invitrogen) on ultra-low attachment plates. Spheroids were
dissociated and passaged every 6–8 days. A total of 16106 C666-1
cells were seeded per well and the number of spheroids formed was
counted.
Five endoscopic tumor biopsies for FACS analysis were
obtained from NPC patients with written consents in the
Department of Otorhinolaryngology, Prince of Wales Hospital,
CUHK. All cases were positive for EBER-in situ hybridization and
histologically diagnosed as undifferentiated or poorly differentiated
NPC. We also recruited 49 archival formalin-fixed paraffin-
embedded primary tumors from the tissue bank of Department of
Anatomical & Cellular Pathology, CUHK for immunohistochem-
ical (IHC) staining. The study protocol was approved by the
Clinical Research Ethics Committee of the Chinese University of
Hong Kong.
Quantitative Reverse Transcription and Polymerase Chain
Reaction (qRT-PCR) Analysis
Total RNAs were extracted using the Qiagen RNeasy kit
(Qiagen) and reverse-transcribed into cDNA using SuperScript
cDNA Synthesis Kit (Invitrogen) according to manufacturer
protocol. Quantitative RT-PCR were then carried out with
specific primers (Invitrogen, primer sequences as listed in Table
S1) and Power SYBRH Green PCR mix (Applied Biosystems). b-
actin expression was used for data normalization. All qRT-PCRs
were performed in triplicates on an ABI 7500 real-time PCR
system (Applied Biosystems) as instructed by the manufacturer.
Fluorescence-activated Cell Sorting (FACS) Analysis
Single cell suspensions obtained from cell lines and tumor tissues
were rinsed twice and resuspended in PBS (105 to 106 cells/
100 ml). For intracellular staining, cells were fixed in 70% ethanol
for 24 hours at 220uC before rehydrating with PBS. Cells were
subjected to blocking of non-specific epitopes by 2% human serum
and labeled with fluorochrome-conjugated antibodies. Anti-CD44
and anti-CCR7 (BD Pharmingen), and anti-SOX2 (R&D Systems)
were used in this study. Respective mouse or rat IgG isotypic
controls were included in the experiment. For each sample, at least
10,000 cells were acquired and analyzed with a BD FACSAria
flow cytometer (BD Biosciences) and Flowjo software (Treestar).
Magnetic-activated Cell Sorting (MACS) of CD44+ and
CD442 Cells
CD44-positive (CD44+) and CD44-negative (CD442) C666-1
cells were separated by using anti-CD44 magnetic bead-coupled
antibody and the magnetic-activated cell sorting (MACS) system
(Miltenyi Biotec). Briefly, cells were incubated with 20 ml of anti-
CD44 microbeads (Miltenyi Biotec) per 16107 cells for 30 minutes
at 4uC. Subsequently, cells were washed with PBS supplemented
with 0.5% FBS and applied into MACS LS separation columns
(Miltenyi Biotec). Purity of CD44+ and CD442 fractions obtained
was confirmed by FACS analysis.
Clone Formation Assay
A total of 16103 isolated/treated or parental/untreated cells
were seeded into 100 mm2 plates and cultured for 7–10 days. Cells
were then washed with PBS, fixed in methanol for 10 min, and
stained with Giemsa stain. Experiments were performed in
triplicates and colonies showing size of larger than 50 cells were
counted and compared between the two groups.
Chemoresistant Assays
A total of 56102 isolated/treated or parental/untreated C666-1
cells were seeded into 96-well plate and cultured for 24 hrs in
complete RPMI-1640 medium. The cells were then treated with
0–2.5 mg/mL 5-fluorouracil (5-FU) or non-treated as control as
Table 3. Correlation between CCR7 expression and clinicopathological features in primary tumors.
Variables No. of patients
CCR7 expression score
(mean, {no. of patients}) P-value
Score =0 group Scores .0 group
Age (years)
#50 20 0 {2} 4.7 {18} P=0.99
.50 19 0 {6} 5.7 {13}
Gender
Male 30 0 {7} 4.9 {23} P=0.05
Female 9 0 {1} 5.9 {8}
Clinical stage
Early (Stage 1,2) 14 0 {3} 6.5 {11} P=0.32
Late (Stage 3,4) 25 0 {5} 4.4 {20}
Recurrence/distant metastasis
Absent 30 0 {7} 5.5 {23} *P= 0.03
Present 9 0 {1} 4.1 {8}
N/A: Data not available.
*Spearman correlation test applied, with P-value ,0.05 considered statistical significant.
doi:10.1371/journal.pone.0052426.t003
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described [37]. The cells were subjected to WST1 cell proliferation
assay after 24 hrs of drug treatment. The absorbance measured
indicated the proliferation rate of the treated cells and results were
compared between CD44+/CD442 or treated/untreated cells.
In vivo Tumorigenicity Assay in Nude Mice
To evaluate the tumorigenic potential, sphere-forming, mono-
layer parental C666-1 cells were counted, resuspended, and
injected subcutaneously into 4-week-old female nude athymic
mice. Mice were inspected daily for tumor formation. After 4 to
12 weeks, mice were sacrificed and the tumors retrieved.
Microarray Analysis
Total RNA was extracted from sphere-forming and parental
C666-1 cells as mentioned above. The Whole Human Genome
Oligo Microarray, with over 41000 probes (Agilent Technologies),
was used for expression analysis. The expression analysis was
carried out according to the manufacturer’s protocol. cRNA
samples of sphere-forming and parental C666-1 were labeled with
5-CTP (Cy5) and cyanine 3-CTP (Cy-3), respectively. Microarrays
were scanned on Agilent’s dual-laser microarray scanner and
obtained data were normalized and analyzed using GeneSpring
GX version 9.0.5 software (Agilent Technologies). Gene Ontology
(GO) analysis of differentially expressed genes was performed by
DAVID (The Database for Annotation, Visualization and In-
tegrated Discovery) v6.7 (david.abcc.ncifcrf.gov).
Immunohistochemistry
For immunohistochemical analysis, anti-CCR7 (Lifespan
Biosciences) antibodies were used to determine the CCR7
expression in NPC primary biopsies as previously described
[38]. Positive cells were counted and scored according to their
prevalence and intensity among tumor cells. The CCR7
expression score was the product of proportion and intensity
scores, ranging from 0 to 12. The CCR7 expression was
categorized into absence (score 0), low (score 1–3), intermediate
(score 4–6), and high (score 7–12). The score was correlated
with respective clinical parameters.
Immunofluorescence Staining
NPC-derived spheroids were transferred onto slide-chambers
after 4 weeks of selection and were further cultured for 3 days
before fixing with 4% paraformaldehyde for staining. The fixed
cells underwent permeabilization with 1% triton-100 in PBS. They
were then blocked with 10% rabbit serum in PBS before
incubating in anti-human FITC-conjugated CD44 antibody (BD
Pharmingen) at 4uC in dark. Excess antibodies were washed away
by PBS and then cells were fixed again using 4% paraformalde-
hyde. Cells were finally mounted in VECTASHIELDH Mounting
Medium with DAPI (Vector Laboratories).
Neutralization of CCR7
To determine the function of CCR7, C666-1 cells were treated
with IgG or CCR7 blocking antibody (R&D) and then collected
for proliferation and spheroid formation assays.
Statistical Analysis
All in vitro tests were repeated using at least three independent
samples for statistical calculations. Unless otherwise stated, un-
paired t-test was used for statistical analysis of data. Comparison of
IHC scores with clinical data was calculated by Spearman’s
correlation. Statistical significance (P-value of ,0.05) was de-
Figure 6. Effect of CCR7 neutralization on NPC CSCs. To evaluate
the function of CCR7 in CSCs, C666-1 was treated with CCR7 blocking
antibody and its proliferation, clone-forming and sphere-forming
efficiency were investigated. (A) Proliferation of CD44+ cells was
inhibited after treatment with CCR7 blocking antibody. (B) The clone
formation efficiency of C666-1 cells was diminished after CCR7 blocking
and (C) the spheroid-forming ability was significantly inihibited
(P,0.001) when compared to untreated controls. Histograms denoting
mean 6 SE (n$3) with statistical significance calculated by t-test
(*P,0.05, ***P,0.001).
doi:10.1371/journal.pone.0052426.g006
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termined by PRISM5 (Graphpad Software) and presented
graphically as mean 6 standard error (SE).
Supporting Information
Figure S1 CD44 expression in C666-1 spheroids. CD44
expression was detected on C666-1 spheroids by immunofluores-
cence staining. CD44 expression was denoted in green by
fluorescence FITC while nucleus in blue with DAPI. Negative
control was demonstrated by staining with non-specific IgG
binding.
(TIF)
Figure S2 CD133+ cells in NPC. By flow cytometry, CD133-
expressing cells were found to be enriched in sphere-forming
C666-1 when compared to NPC cell lines and primary tumors (all
P,0.001).
(TIF)
Figure S3 Purity of CD44+ and CD442 cell fractions
after MACS separation. By flow cytometry, CD44 expression
was confirmed to be enriched (.70%) in CD44+ cell fractions
after MACS separation.
(TIF)
Figure S4 Correlation of CCR7 and CD44 expression in
NPC primary tumors. A significant linear relationship between
CCR7 and CD44 expression was determined in 39 primary cases
of NPC (Spearman correlation: r = 0.676, P,0.001)
(TIF)
Figure S5 Expression of CSC marker CD44 and ABC
drug transporters in drug-resistant C666-1. By qRT-PCR,
it was found that CD44+ cells were significantly higher in both
cisplatin- and doxorubicin-resistant C666-1 lines than that in
parental C666-1. In addition, they were also enriched in ABC
transporters ABCC3 and ABCC11. Histograms denoting mean 6
SE (n$3) with statistical significance calculated by t-test (*P,0.05,
**P,0.01, ***P,0.001).
(TIF)
Table S1 Table listing the qPCR primer sequences used
in this study.
(DOCX)
Table S2 Gene ontology analysis of microarray data.
(DOCX)
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